Laboratoire X.O

Laboratoire X.O, also known as LXO, is a dynamic pharmaceutical entity that has been acting for health since its inception in 2015. With a commitment to ensuring access, availability, and quality of essential medicines, LXO stands at the forefront of the healthcare industry.

Core Values and Commitments

• Quality, Ethics, and Transparency: At the heart of LXO's operations lies a steadfast commitment to these principles, ensuring that every action and decision upholds the highest standards.
• Innovation and Agility: LXO prides itself on its ability to adapt and respond to the ever-evolving needs of the healthcare sector, driving progress and innovation.

Therapeutic Areas

LXO has made significant strides in various therapeutic areas, including:

• Cardiology
• Central Nervous System
• Internal Medicine

Key Figures

• 20 add-ons since 2015
• Over €90M in turnover
• 18 brands and 26 products
• Presence in over 80+ countries
• A dedicated team of 40+ collaborators across France, Ireland, and the US

Milestones and Achievements

• Acquisition of Nimotop®: Marking a significant milestone, LXO acquired the prescription drug Nimotop® from Bayer, expanding its portfolio and international footprint.
• Expansion: To accommodate its growth, LXO moved to new premises, fostering an environment conducive to creativity and collaboration.

Global Presence

With headquarters in Île-de-France, LXO has established a robust presence across the globe, including strategic expansions in the US and the acquisition of Noden Pharma DAC in Dublin, enhancing its European market expertise.

Future Outlook

LXO continues to pursue opportunities for growth, both organically and through external avenues, with a clear focus on delivering life-saving drugs and maintaining its reputation as a leader in the pharmaceutical industry.